PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-57.23%
Both companies show declining revenue. Martin Whitman would check for industry-wide issues.
No Data
No Data available this quarter, please select a different quarter.
-57.23%
Both companies show declining gross profit. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-15.08%
R&D reduction while TRVN shows 30.84% growth. Joel Greenblatt would examine competitive risk.
-0.47%
G&A reduction while TRVN shows 43.12% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.89%
Operating expenses reduction while TRVN shows 39.88% growth. Joel Greenblatt would examine advantage.
-10.89%
Total costs reduction while TRVN shows 40.18% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
3.20%
D&A growth above 1.5x TRVN's 0.98%. Michael Burry would check for excessive investment.
5.74%
EBITDA growth while TRVN declines. John Neff would investigate advantages.
-120.42%
Both companies show margin pressure. Martin Whitman would check industry conditions.
5.53%
Operating income growth while TRVN declines. John Neff would investigate advantages.
-120.91%
Both companies show margin pressure. Martin Whitman would check industry conditions.
3.85%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
5.62%
Pre-tax income growth while TRVN declines. John Neff would investigate advantages.
-120.69%
Both companies show margin pressure. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
5.62%
Net income growth while TRVN declines. John Neff would investigate advantages.
-120.69%
Both companies show margin pressure. Martin Whitman would check industry conditions.
13.79%
EPS growth while TRVN declines. John Neff would investigate advantages.
13.79%
Diluted EPS growth while TRVN declines. John Neff would investigate advantages.
10.10%
Share count reduction below 50% of TRVN's 1.78%. Michael Burry would check for concerns.
10.10%
Diluted share reduction below 50% of TRVN's 1.78%. Michael Burry would check for concerns.